Skip to main content
Site Search
Close Search
See More

RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Digital PCR

Digital is the new absolute

Who we are

Learn about who we are and what we do to make improvements in life possible.

Join the QIAGEN team

Latest information on COVID-19

News, testing solutions and stories covering global efforts in the fight against COVID-19.

Our stories

Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances.

    Market Strategy

    Read our equity story, financial disclosures and how we create shareholder value.

      Latest News

      Read up on our latest press releases or peruse our various media archives.

      Contact Us

      Thank you for choosing QIAGEN. If you have questions about QIAGEN, our products or your order, this page should help you find the answers and contacts you need.

      Overview

      Equity Story

      Home  >  Investor Relations  >  At a Glance  >  Equity Story

      Commitment to solid profitable growth

      QIAGEN is executing a strategy to deliver solid profitable growth through 2028, supported by:

      This positions QIAGEN as a leading provider of high-quality Sample to Insight solutions for customers across Life Sciences and Molecular Diagnostics. Our products empower scientists and clinicians worldwide to unlock molecular insights from the building blocks of life, and our premium brand is trusted by students and Nobel Prize Laureates alike.

      Growth pillars positioned for top performance in attractive markets

      QIAGEN is advancing its growth through a focused and disciplined strategy powered by well-defined growth pillars. The growth pillars are driving our 2028 growth expansion with clear financial targets and alignment with expanding global market trends.

      Learn more about our 2028 commitments

      These growth pillars contribute at least $2 bn in projected net sales CER by 2028. We remain focused on expanding our market share and maintaining top-tier leadership positions by leveraging our proven expertise.

      Margin expansion through digital-led excellence

      QIAGEN is executing broad initiatives driving profitability and maximizing efficiency gains through targeted resource allocation. The focus is on reinvesting in high-growth areas while continuing to deliver gains in profitability.

      Disciplined capital allocation to enhance portfolio and increase returns

      QIAGEN’s capital strategy reinforces investor trust:

      With a healthy balance sheet, a strong cash flow and well-balanced debt maturities, QIAGEN has the flexibility to pursue strategic opportunities while creating long-term value for shareholders.

      Empowered culture and strong leadership team

      At QIAGEN, our dedicated employees, proudly known as QIAGENers, are united by a single vision: Making improvements in life possible. We are on track for the next phase of growth while maintaining our core strengths.